TN2009000145A1 - Compositions and methods for modulating c-kit and pdgfr receptors - Google Patents

Compositions and methods for modulating c-kit and pdgfr receptors

Info

Publication number: TN2009000145A1
Authority: TN; Tunisia
Prior art keywords: methods; raf; kit; pdgfr; compounds
Prior art date: 2006-10-20

Application number

TNP2009000145A

Other languages

English (en)

Inventor

Donatella Chianelli

Christopher Cow

Yun He

Songchun Jiang

Xiaolin Li

Xiaodong Liu

Zuosheng Liu

Jon Loren

Valentina Molteni

Juliet Nabakka

Pingda Ren

Taebo Sim

Xiaodong Wang

Shuli You

Original Assignee

Irm Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-20

Filing date

2009-04-17

Publication date

2010-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39027274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000145(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-04-17 Application filed by Irm Llc filed Critical Irm Llc

2010-10-18 Publication of TN2009000145A1 publication Critical patent/TN2009000145A1/fr

Links

102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title abstract 2
108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title abstract 2
101150093908 PDGFRB gene Proteins 0.000 title 1
239000000203 mixture Substances 0.000 title 1
102000005962 receptors Human genes 0.000 title 1
108020003175 receptors Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
-1 CSFlR Proteins 0.000 abstract 2
101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 abstract 2
102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 abstract 2
230000002159 abnormal effect Effects 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 abstract 1
102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 abstract 1
101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 abstract 1
101150036586 FES gene Proteins 0.000 abstract 1
102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 abstract 1
101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 abstract 1
101100457333 Homo sapiens MAPK11 gene Proteins 0.000 abstract 1
101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 abstract 1
101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 abstract 1
101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 abstract 1
101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 abstract 1
101150028321 Lck gene Proteins 0.000 abstract 1
108700036166 Mitogen-Activated Protein Kinase 11 Proteins 0.000 abstract 1
102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 abstract 1
102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 abstract 1
102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 abstract 1
102100039810 Protein-tyrosine kinase 6 Human genes 0.000 abstract 1
108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 abstract 1
102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 abstract 1
102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
101150046814 SAPK2 gene Proteins 0.000 abstract 1
108060006706 SRC Proteins 0.000 abstract 1
101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 abstract 1
108010009583 Transforming Growth Factors Proteins 0.000 abstract 1
102100031167 Tyrosine-protein kinase CSK Human genes 0.000 abstract 1
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
230000002074 deregulated effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 abstract 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
239000003909 protein kinase inhibitor Substances 0.000 abstract 1
102000009929 raf Kinases Human genes 0.000 abstract 1
108010077182 raf Kinases Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Oncology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Addiction (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
AIDS & HIV (AREA)

TNP2009000145A 2006-10-20 2009-04-17 Compositions and methods for modulating c-kit and pdgfr receptors TN2009000145A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US86243006P	2006-10-20	2006-10-20
PCT/US2007/081538 WO2008051757A1 (fr)	2006-10-20	2007-10-16	Compositions et procédés de modulation de récepteurs de c-kit et de facteur de croissance dérivé de plaquettes (pdgfr)

Publications (1)

Publication Number	Publication Date
TN2009000145A1 true TN2009000145A1 (en)	2010-10-18

Family

ID=39027274

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000145A TN2009000145A1 (en)	2006-10-20	2009-04-17	Compositions and methods for modulating c-kit and pdgfr receptors

Country Status (25)

Country	Link
US (2)	US7678792B2 (fr)
EP (1)	EP2076513A1 (fr)
JP (1)	JP2010506948A (fr)
KR (1)	KR101079520B1 (fr)
CN (1)	CN101528744A (fr)
AR (1)	AR063343A1 (fr)
AU (1)	AU2007309279B2 (fr)
BR (1)	BRPI0718162A2 (fr)
CA (1)	CA2667010A1 (fr)
CL (1)	CL2007003005A1 (fr)
CO (1)	CO6170361A2 (fr)
CR (1)	CR10717A (fr)
EA (1)	EA200900573A1 (fr)
EC (1)	ECSP099353A (fr)
IL (1)	IL197875A0 (fr)
MA (1)	MA30888B1 (fr)
MX (1)	MX2009004141A (fr)
NI (1)	NI200900061A (fr)
NO (1)	NO20091949L (fr)
PE (1)	PE20081262A1 (fr)
SM (1)	SMP200900027B (fr)
TN (1)	TN2009000145A1 (fr)
TW (1)	TW200825081A (fr)
WO (1)	WO2008051757A1 (fr)
ZA (1)	ZA200902711B (fr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003078448A1 (fr)	2002-03-13	2003-09-25	Signum Biosciences, Inc.	Modulation de la methylation de proteines et du phosphate des phosphoproteines
WO2006084033A1 (fr)	2005-02-03	2006-08-10	Signum Biosciences, Inc.	Compositions et procedes pour l'amelioration de la fonction cognitive
US7923041B2 (en)	2005-02-03	2011-04-12	Signum Biosciences, Inc.	Compositions and methods for enhancing cognitive function
US7897762B2 (en)	2006-09-14	2011-03-01	Deciphera Pharmaceuticals, Llc	Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) *	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP5411703B2 (ja)	2006-11-09	2014-02-12	アルコンリサーチ，リミテッド	薬物送達のための水不溶性ポリマーマトリクス
TWI498115B (zh) *	2007-12-27	2015-09-01	Daiichi Sankyo Co Ltd	咪唑羰基化合物
EP2252612B1 (fr) *	2008-02-22	2012-03-28	Irm Llc	Composés et compositions hétérocycliques comme inhibiteurs de c-kit et pdgfr kinase
CN102014897B (zh)	2008-04-21	2015-08-05	西格纳姆生物科学公司	化合物、组合物和其制备方法
FR2930552B1 (fr) *	2008-04-24	2012-10-12	Centre Nat Rech Scient	N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
EA201001847A1 (ru) *	2008-06-11	2011-08-30	Айрм Ллк	Соединения и композиции, применяемые для лечения малярии
US20110200597A1 (en) *	2008-08-05	2011-08-18	George Mason Intellectual Properties, Inc.	Signal pathway alterations and drug target elevations in primary metachronous metastatic colorectal cancer compared to non-metastatic disease
CA2742007C (fr) *	2008-10-29	2014-07-08	Deciphera Pharmaceuticals, Llc	Amides de cyclopropane et analogues presentant des activites anticancereuses et antiproliferatives
AR074776A1 (es) *	2008-12-18	2011-02-09	Sanofi Aventis	Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
WO2010071846A2 (fr)	2008-12-19	2010-06-24	Afraxis, Inc.	Composés pour traiter des états neuropsychiatriques
EP2396324A1 (fr) *	2009-02-13	2011-12-21	Fovea Pharmaceuticals	Ý1, 2, 4¨triazolo ý1, 5 -a¨pyridines servant d'inhibiteurs de kinases
CN102648200A (zh)	2009-10-09	2012-08-22	亚弗克希斯公司	用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2，3-d]嘧啶-7(8h)-酮
CA2786245A1 (fr)	2010-01-29	2011-08-04	Boehringer Ingelheim International Gmbh	Naphtyridines substituees et leur utilisation comme inhibiteurs de syk kinase
WO2011097526A1 (fr)	2010-02-05	2011-08-11	Irm Llc	Composés et compositions comme inhibiteurs de protéine-kinases
US20120189633A1 (en) *	2011-01-26	2012-07-26	Kolltan Pharmaceuticals, Inc.	Anti-kit antibodies and uses thereof
JP5902293B2 (ja)	2011-04-25	2016-04-13	アッシャー・サード・イニシアティブ・インコーポレイテッド	ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法
PH12014500209A1 (en) *	2011-07-26	2014-03-03	Boehringer Ingelheim Int	Substituted quinolines and their use as medicaments
AU2012315953A1 (en) *	2011-09-30	2014-04-03	Kineta, Inc.	Anti-viral compounds
WO2013171640A1 (fr)	2012-05-15	2013-11-21	Novartis Ag	Dérivés de benzamide pour inhiber l'activité d'abl1, d'abl2 et de bcr-abl2
ES2670601T3 (es)	2012-05-15	2018-05-31	Novartis Ag	Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1
KR20150008406A (ko)	2012-05-15	2015-01-22	노파르티스 아게	Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
MX357305B (es)	2012-05-15	2018-07-04	Novartis Ag	Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
US8461179B1 (en)	2012-06-07	2013-06-11	Deciphera Pharmaceuticals, Llc	Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR101652229B1 (ko) *	2012-06-07	2016-08-30	데시페라 파마슈티칼스, 엘엘씨.	증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물
EP4063391A1 (fr)	2012-07-25	2022-09-28	Celldex Therapeutics, Inc.	Anticorps anti-kit et leurs utilisations
US9227976B2 (en)	2012-10-25	2016-01-05	Usher Iii Initiative, Inc.	Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
AU2014302458A1 (en) *	2013-06-26	2015-12-24	Proteostasis Therapeutics, Inc.	Methods of modulating CFTR activity
GB201401886D0 (en)	2014-02-04	2014-03-19	Lytix Biopharma As	Neurodegenerative therapies
CA2942386A1 (fr)	2014-03-13	2015-09-17	Proteostasis Therapeutics, Inc.	Composes, compositions et procedes pour augmenter l'activite du cftr
AU2015229117A1 (en)	2014-03-13	2016-09-29	Proteostasis Therapeutics, Inc.	Compounds, compositions, and methods for increasing CFTR activity
JP6768639B2 (ja)	2014-05-23	2020-10-21	セルデックスセラピューティクス，インコーポレーテッド	好酸球又はマスト細胞関連障害の治療
EP3157917B1 (fr)	2014-06-19	2020-03-18	Proteostasis Therapeutics, Inc.	Composés, compositions et procédés pour augmenter l'activité du cftr
CN111170998B (zh)	2014-11-05	2023-04-11	益方生物科技(上海)股份有限公司	嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016105468A1 (fr)	2014-12-23	2016-06-30	Proteostasis Therapeutics, Inc.	Dérivés de 3-hétéroarylisoxazol-5-amide carboxylique utiles dans le traitement, entre autres, d'une fibrose kystique
US10738011B2 (en)	2014-12-23	2020-08-11	Proteostasis Therapeutics, Inc.	Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr)	2014-12-23	2017-10-31	Proteostasis Therapeutics Inc	Composés, compositions et procédés pour augmenter l'activité du cftr
WO2016105477A1 (fr)	2014-12-23	2016-06-30	Proteostasis Therapeutics, Inc	Dérivés d'amides 5-phényl- ou 5-hétéroarylthiazol-2-carboxyliques servant au traitement, entre autres, de la fibrose cystique
US10548878B2 (en)	2015-07-24	2020-02-04	Proteostasis Therapeutics, Inc.	Compounds, compositions, and methods of increasing CFTR activity
CN105664178B (zh) *	2015-09-24	2019-08-20	洪健	Syk作为肝纤维化/硬化治疗靶点的应用
SG11201802798WA (en)	2015-10-06	2018-05-30	Proteostasis Therapeutics Inc	Compounds, compositions, and methods for modulating cftr
CN107286077B (zh)	2016-04-01	2021-04-02	合肥中科普瑞昇生物医药科技有限公司	一种选择性的c-kit激酶抑制剂
WO2017177124A1 (fr)	2016-04-07	2017-10-12	Proteostasis Therapeutics, Inc.	Atomes de silicone contenant des analogues d'ivacaftor
ES2954658T3 (es)	2016-06-21	2023-11-23	Proteostasis Therapeutics Inc	Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR
EP3535243B1 (fr) *	2016-11-04	2021-12-15	Auckland Uniservices Limited	Dérivés de 9h-xanthén-9-one, 9h-thioxanthen-9-one et acridin-9(10h)-one substitués et composés similaires en tant qu'inhibiteurs csf-1r pour le traitement du cancer
MA49014A (fr) *	2017-03-21	2020-02-05	Arbutus Biopharma Corp	Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
PL3621615T3 (pl)	2017-05-12	2024-03-25	Enanta Pharmaceuticals, Inc.	Inhibitory regulujące sygnał apoptozy kinazy 1 i sposoby ich stosowania
BR112019025346A2 (pt) *	2017-05-30	2020-06-30	Deciphera Pharmaceuticals, Inc.	uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin-3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas
CN111094286B (zh) *	2017-09-20	2022-07-29	浙江海正药业股份有限公司	1,2-二氢-1,6-萘啶类衍生物、其制备方法及其在医药上的用途
RU2764243C2 (ru)	2017-09-22	2022-01-14	ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи	Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh)	2017-10-18	2023-03-07	朱比兰特埃皮帕德有限公司	作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en)	2017-11-06	2023-04-18	Jubilant Prodell Llc	Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr)	2017-11-24	2024-06-28	Jubilant Episcribe Llc	Heterociklična jedinjenja kao inhibitori prmt5
CN118903436A (zh)	2018-01-31	2024-11-08	德西费拉制药有限责任公司	治疗肥大细胞增多症的组合疗法
KR102708177B1 (ko)	2018-01-31	2024-09-23	데시페라 파마슈티칼스, 엘엘씨.	위장관 기질 종양의 치료를 위한 병용 요법
CN112105610B (zh) *	2018-03-13	2024-01-26	朱比连特普罗德尔有限责任公司	作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
IL278368B2 (en)	2018-05-02	2024-06-01	Enanta Pharm Inc	Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10968199B2 (en) *	2018-08-22	2021-04-06	Enanta Pharmaceuticals, Inc.	Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020052349A1 (fr)	2018-09-14	2020-03-19	上海和誉生物医药科技有限公司	Inhibiteur de fgfr, son procédé de préparation et son application
WO2020106707A1 (fr)	2018-11-19	2020-05-28	Enanta Pharmaceuticals, Inc.	Inhibiteurs de la kinase 1 régulant le signal d'apoptose et leurs méthodes d'utilisation
UA128431C2 (uk)	2018-11-26	2024-07-10	Форті Севен, Інк.	ГУМАНІЗОВАНЕ АНТИТІЛО ДО c-Kit
IL330104A (en)	2019-03-11	2026-08-01	Deciphera Pharmaceuticals Llc	Crystalline forms of rifatinib
WO2020198214A1 (fr)	2019-03-25	2020-10-01	Enanta Pharmaceuticals, Inc.	Inhibiteurs de la kinase 1 régulant le signal d'apoptose et leurs procédés d'utilisation
HRP20260411T1 (hr)	2019-08-12	2026-05-08	Deciphera Pharmaceuticals, Llc	Ripretinib za liječenje gastrointestinalnih stromalnih tumora
JP7580123B2 (ja) *	2019-08-25	2024-11-11	国立大学法人山口大学	血管新生関連疾患の予防又は治療用医薬組成物
FI4084779T3 (fi)	2019-12-30	2024-12-16	Deciphera Pharmaceuticals Llc	1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
TW202204354A (zh) *	2020-04-02	2022-02-01	美商普雷辛肯公司	用於ｃｓｋ調節之化合物及方法以及其說明
EP4178580B1 (fr)	2020-07-09	2025-11-05	Usher III Initiative, Inc.	Bf 844 pour l'utilisation dans le traitement du cancer
PE20231311A1 (es)	2020-11-18	2023-08-24	Deciphera Pharmaceuticals Llc	Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
CN115108997A (zh) *	2021-03-22	2022-09-27	南开大学	一类具抑菌活性的磺酰脲类化合物的合成与应用
WO2023050007A1 (fr) *	2021-09-29	2023-04-06	Repare Therapeutics Inc.	Composés n-([(l,3,4-thiadiazolyle) ou (thiazolyle)]-5-substitués)carboxamide (substitué) et leur utilisation pour inhiber la polymérase thêta humaine
MX2024006627A (es)	2021-12-03	2024-08-22	Deciphera Pharmaceuticals Llc	Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos.
TW202342055A (zh)	2022-02-03	2023-11-01	美商奇奈特生物製藥公司	Raf激酶抑制劑
EP4572758A1 (fr) *	2022-08-19	2025-06-25	Purdue Research Foundation	Inhibiteurs des interactions protéine-protéine
US11779572B1 (en)	2022-09-02	2023-10-10	Deciphera Pharmaceuticals, Llc	Methods of treating gastrointestinal stromal tumors
KR20250108598A (ko) *	2022-09-29	2025-07-15	리페어 세라퓨틱스 인크.	N-(5-치환된-[(1,3,4-티아다이아졸릴) 또는 (1,3-티아졸릴)](치환된)카복스아마이드 화합물, 약제학적 조성물, 그리고 아마이드 화합물의 제조 방법 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001292320A1 (en)	2000-10-02	2002-04-15	Tanabe Seiyaku Co., Ltd.	Benzylamine compound, process for producing the same, and intermediate therefor
WO2005034869A2 (fr)	2003-10-08	2005-04-21	Irm Llc	Composes et compositions convenant comme inhibiteurs de proteine-kinases
CA2592116A1 (fr) *	2004-12-23	2006-08-03	Deciphera Pharmaceuticals, Llc	Medicaments anti-inflammatoires
CA2592118C (fr)	2004-12-23	2015-11-17	Deciphera Pharmaceuticals, Llc	Derives d'uree en tant que modulateurs d'enzyme
JP2009537520A (ja) *	2006-05-15	2009-10-29	アイアールエム・リミテッド・ライアビリティ・カンパニー	Ｆｇｆ受容体キナーゼ阻害剤のための組成物および方法
US8188113B2 (en) *	2006-09-14	2012-05-29	Deciphera Pharmaceuticals, Inc.	Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7750007B2 (en) *	2006-11-06	2010-07-06	Supergen, Inc.	Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors

2007
- 2007-10-16 EP EP07844322A patent/EP2076513A1/fr not_active Ceased
- 2007-10-16 KR KR1020097008062A patent/KR101079520B1/ko not_active Expired - Fee Related
- 2007-10-16 US US11/873,196 patent/US7678792B2/en not_active Expired - Fee Related
- 2007-10-16 JP JP2009533484A patent/JP2010506948A/ja active Pending
- 2007-10-16 EA EA200900573A patent/EA200900573A1/ru unknown
- 2007-10-16 BR BRPI0718162-0A patent/BRPI0718162A2/pt not_active IP Right Cessation
- 2007-10-16 CN CNA2007800390373A patent/CN101528744A/zh active Pending
- 2007-10-16 CA CA002667010A patent/CA2667010A1/fr not_active Abandoned
- 2007-10-16 MX MX2009004141A patent/MX2009004141A/es active IP Right Grant
- 2007-10-16 WO PCT/US2007/081538 patent/WO2008051757A1/fr not_active Ceased
- 2007-10-16 AU AU2007309279A patent/AU2007309279B2/en not_active Ceased
- 2007-10-19 CL CL200703005A patent/CL2007003005A1/es unknown
- 2007-10-19 TW TW096139384A patent/TW200825081A/zh unknown
- 2007-10-19 PE PE2007001422A patent/PE20081262A1/es not_active Application Discontinuation
- 2007-10-19 AR ARP070104639A patent/AR063343A1/es unknown
2009
- 2009-03-26 IL IL197875A patent/IL197875A0/en unknown
- 2009-04-16 CR CR10717A patent/CR10717A/es not_active Application Discontinuation
- 2009-04-17 CO CO09039151A patent/CO6170361A2/es not_active Application Discontinuation
- 2009-04-17 TN TNP2009000145A patent/TN2009000145A1/fr unknown
- 2009-04-20 NI NI200900061A patent/NI200900061A/es unknown
- 2009-04-20 ZA ZA200902711A patent/ZA200902711B/xx unknown
- 2009-04-20 SM SM200900027T patent/SMP200900027B/it unknown
- 2009-05-13 MA MA31869A patent/MA30888B1/fr unknown
- 2009-05-19 NO NO20091949A patent/NO20091949L/no not_active Application Discontinuation
- 2009-05-20 EC EC2009009353A patent/ECSP099353A/es unknown
- 2009-12-02 US US12/629,665 patent/US8106068B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ECSP099353A (es)	2009-06-30
AU2007309279A1 (en)	2008-05-02
ZA200902711B (en)	2010-05-26
KR101079520B1 (ko)	2011-11-03
EA200900573A1 (ru)	2009-10-30
CA2667010A1 (fr)	2008-05-02
KR20090054477A (ko)	2009-05-29
MA30888B1 (fr)	2009-11-02
IL197875A0 (en)	2009-12-24
MX2009004141A (es)	2009-05-01
US8106068B2 (en)	2012-01-31
AU2007309279B2 (en)	2011-03-24
US20100081656A1 (en)	2010-04-01
NI200900061A (es)	2010-03-10
US7678792B2 (en)	2010-03-16
CO6170361A2 (es)	2010-06-18
CN101528744A (zh)	2009-09-09
AR063343A1 (es)	2009-01-21
CL2007003005A1 (es)	2008-05-23
EP2076513A1 (fr)	2009-07-08
PE20081262A1 (es)	2008-10-29
CR10717A (es)	2009-07-02
SMAP200900027A (it)	2009-07-14
TW200825081A (en)	2008-06-16
SMP200900027B (it)	2010-01-19
BRPI0718162A2 (pt)	2013-11-26
US20080176846A1 (en)	2008-07-24
WO2008051757A1 (fr)	2008-05-02
NO20091949L (no)	2009-05-19
JP2010506948A (ja)	2010-03-04

Publication	Publication Date	Title
MX2009004141A (es)	2009-05-01	Composiciones y metodos para modular receptores de c-kit y pdgfr.
MX2010002005A (es)	2010-03-11	Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa.
TN2010000087A1 (en)	2011-09-26	5-(4- haloalkoxy) phenyl pyrimidine -2- aminecompounds and compositons as kinase inhibitors
TNSN06406A1 (en)	2008-02-22	Compounds and compositions as protein kinase inhibitors
WO2005034869A3 (fr)	2005-07-07	Composes et compositions convenant comme inhibiteurs de proteine-kinases
TW200637547A (en)	2006-11-01	Compounds and compositions as protein kinase inhibitors
MX2008001969A (es)	2008-04-11	Compuestos y composiciones como inhibidores de proteina cinasa.
PL2027123T3 (pl)	2011-09-30	Związki i kompozycje jako inhibitory kinaz białkowych
WO2006124731A3 (fr)	2007-03-29	Composes et compositions utilise(e)s en tant qu'inhibiteurs de proteines-kinases
MX2008002165A (es)	2008-04-29	Compuestos y composiciones como inhibidores de la proteina cinasa.
NO20091759L (no)	2009-07-01	Forbindelser og sammensetninger som protein kinase inhibitorer
MX2009003649A (es)	2009-04-22	Inhibidores de cinasa de proteina y metodos para utilizarlos.
TW200726766A (en)	2007-07-16	Compounds and compositions as protein kinase inhibitors
TNSN07176A1 (en)	2008-11-21	Compounds and compositions as protein kinase inhibitors
MX2009013782A (es)	2010-02-01	Inhibidores de cinasa de proteina y metodos para el uso de los mismos.
WO2005039486A3 (fr)	2006-03-16	Composes et compositions servant d'inhibiteurs de la proteine kinase
MX2008001605A (es)	2008-04-14	Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica.
BRPI0512422A (pt)	2008-03-04	compostos e composições como inobidores da proteìna quinase
WO2005030151A3 (fr)	2005-09-09	Composes et compositions utiles comme inhibiteurs de la proteine kinase
DOP2009000083A (es)	2009-06-30	Composiciones y metodos para modular recpetores de pdgfr y c-kit
TH98294A (th)	2009-09-17	องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์